Daewoong Pharmaceutical Approves Phase 3 of’Hoy Star Tablet’ that can respond to the COVID-19 mutant

[데일리포스트=송협 선임기자] “Hoystar tablets are easy to take orally and are expected to be highly effective in the initial process of virus replication. Above all, it is expected to provide optimal treatment options to prevent the spread of COVID-19 infection as it is predicted to respond to virus mutations.” (Daewoong Pharmaceutical official)

Daewoong Pharmaceutical has received approval from the Ministry of Food and Drug Safety for a phase 3 clinical trial of’Hoy Star Tablet’ to prevent COVID-19.

This clinical trial is conducted as a large-scale phase 3 clinical trial targeting close contacts exposed to the Corona 19 virus, and a total of 1012 people are randomly assigned and placebo-controlled, and among them, it is conducted at Samsung Seoul Hospital and Asan Hospital in a blinding method, and administration will begin next month. Is expected.

Hoystar tablet is a drug that has passed the mechanism of preventing the virus from entering the human body from entering the cells, inhibiting the proliferation of the virus and improving inflammation.

In Korea, it has been prescribed to patients for more than 10 years and has proven its safety, and it has the advantage of being convenient to take as an oral formulation. In addition, when considering the mechanism of action that blocks the entry of the virus by inhibiting the activity of the protease required for the entry of the virus into the cell, it is possible to respond regardless of the virus mutation, which is a recent issue.

Accordingly, Daewoong Pharmaceutical’s position is that it can expect infection prevention effects for close contacts, including medical staff, self-isolators, and elderly people with weak immunity fr.

Meanwhile, Daewoong Pharmaceutical confirmed the effect of rapid virus removal and improvement of clinical symptoms through the initial phase 2 clinical trial conducted on mild patients with COVID-19, and is continuing late clinical trials for large-scale patients.

Copyright © Global News Media Channel Daily Post Unauthorized reproduction and redistribution prohibited

Source